The full FDA clinical hold formally halts all tests of Aardvark Therapeutics’ drug for Prader-Willi syndrome, a rare inherited metabolic disorder that leads to excessive eating. Earlier this year, Aardvark voluntarily paused all tests of its small molecule after a cardiovascular problem emerged in a healthy volunteer.
GLP-1 drugs dominate the obesity market, but Aardvark Therapeutics aims to curb appetite by going after a different target: TAS2 receptors in the gut. The biotech’s lead drug candidate is in Phase 3 testing in Prader-Willi syndrome, a genetic disorder that causes persistent hunger leading to overeating.
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!